TWD 32.3
(1.1%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 187.43 Million TWD | 48.54% |
2022 | 126.18 Million TWD | 89.94% |
2021 | 66.43 Million TWD | 64.41% |
2020 | 40.4 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 FY | 187.43 Million TWD | 48.54% |
2023 Q4 | 187.43 Million TWD | 99.52% |
2023 Q2 | 93.94 Million TWD | -25.55% |
2022 Q4 | 126.18 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
BIONET Corp. | 626.46 Million TWD | 70.08% |
DIVA Laboratories, Ltd. | 210.93 Million TWD | 11.139% |
Genetics Generation Advancement Corp. | 164.9 Million TWD | -13.662% |
Welgene Biotech Co.,Ltd. | 247.89 Million TWD | 24.389% |
Puriblood Medical Co., Ltd. | 84.35 Million TWD | -122.21% |